Phospho-PI3K p85 (Tyr458)[Tyr467]/p55 (Tyr199) Antibody

製品:	Phospho-PI3K p85 (Tyr458)[Tyr467]/p55 (Tyr199) Antibody
カタログ:	AF3242
タンパク質の説明:	Rabbit polyclonal antibody to Phospho-PI3K p85 (Tyr458)[Tyr467]/p55 (Tyr199)
アプリケーション:	WB IHC IF/ICC
反応性:	Human, Mouse, Rat, Monkey
予測:	Zebrafish, Bovine, Horse, Sheep, Rabbit, Dog, Chicken, Xenopus
分子量:	54kDa,84kDa; 84kD,54kD(Calculated).
ユニプロット:	P27986 \| Q92569
RRID:	AB_2834668

類似製品を見る>>

サイズ	価格	在庫状況
100ul	$280	在庫あり
200ul	$350	在庫あり

プロトコル

製品説明

ソース:

Rabbit

アプリケーション:

WB 1:500-1:2000, IF/ICC 1:100-1:500, IHC 1:50-1:200
*The optimal dilutions should be determined by the end user.
*Tips:

WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.

反応性:

Human,Mouse,Rat,Monkey

予測:

Zebrafish(100%), Bovine(86%), Horse(86%), Sheep(86%), Rabbit(100%), Dog(86%), Chicken(86%), Xenopus(86%)

クローナリティ:

Polyclonal

特異性:

Phospho-PI3K p85(Tyr458)/p55(Tyr199) Antibody detects endogenous levels of PI3K p85/p55 only when phosphorylated at Tyr467(p85) or Tyr199(p55). The site Tyr467 was historically referenced as Tyr458.

RRID:

AB_2834668
引用形式: Affinity Biosciences Cat# AF3242, RRID:AB_2834668.

コンジュゲート:

Unconjugated.

精製:

The antibody is from purified rabbit serum by affinity purification via sequential chromatography on phospho-peptide and non-phospho-peptide affinity columns.

保存:

Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at -20 °C. Stable for 12 months from date of receipt.

別名:

折りたたみ／展開

GRB 1; GRB1; p85 alpha; p85; P85A_HUMAN; Phosphatidylinositol 3 kinase associated p 85 alpha; Phosphatidylinositol 3 kinase regulatory 1; Phosphatidylinositol 3 kinase regulatory subunit alpha; Phosphatidylinositol 3 kinase regulatory subunit polypeptide 1 (p85 alpha); Phosphatidylinositol 3-kinase 85 kDa regulatory subunit alpha; Phosphatidylinositol 3-kinase regulatory subunit alpha; Phosphoinositide 3 kinase regulatory subunit 1 (alpha); Phosphoinositide 3 kinase regulatory subunit 1 (p85 alpha); Phosphoinositide 3 kinase regulatory subunit 1; Phosphoinositide 3 kinase regulatory subunit polypeptide 1 (p85 alpha); PI3 kinase p85 subunit alpha; PI3-kinase regulatory subunit alpha; PI3-kinase subunit p85-alpha; PI3K; PI3K regulatory subunit alpha; Pik3r1; PtdIns 3 kinase p85 alpha; PtdIns-3-kinase regulatory subunit alpha; PtdIns-3-kinase regulatory subunit p85-alpha; DKFZp686P05226; FLJ41892; OTTHUMP00000009783; OTTHUMP00000009786; p55; p55 gamma; P55G_HUMAN; p55PIK; Phosphatidylinositol 3 kinase regulatory subunit gamma; Phosphatidylinositol 3 kinase regulatory subunit polypeptide 3; Phosphatidylinositol 3 kinase, regulatory subunit, polypeptide 3 (p55, gamma); Phosphatidylinositol 3-kinase 55 kDa regulatory subunit gamma; Phosphatidylinositol 3-kinase regulatory subunit gamma; Phosphoinositide 3 kinase regulatory subunit 3 (gamma); Phosphoinositide 3 kinase regulatory subunit 3; Phosphoinositide 3 kinase regulatory subunit polypeptide 3; Phosphoinositide 3 kinase, regulatory subunit 3 (p55, gamma); Phosphoinositide 3 kinase, regulatory subunit, polypeptide 3 (p55, gamma); PI3 kinase p85 subunit gamma; PI3-kinase regulatory subunit gamma; PI3-kinase subunit p55-gamma; PI3K regulatory subunit gamma; Pik3r3; PtdIns 3 kinase p85 gamma; PtdIns-3-kinase regulatory subunit gamma; PtdIns-3-kinase regulatory subunit p55-gamma;

免疫原

免疫原:

Uniprot:

P27986(P85A_HUMAN) >>Visit HPA database.

Q92569(P55G_HUMAN) >>Visit HPA database.

遺伝子(ID):

PIK3R1(5295) | PIK3R3(8503)

発現特異性:

P27986 P85A_HUMAN:

Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level).

Q92569 P55G_HUMAN:

Highest levels in brain and testis. Lower levels in adipose tissue, kidney, heart, lung and skeletal muscle.

タンパク質の説明:

PIK3R1 is a regulatory subunit of phosphoinositide-3-kinase. Mediates binding to a subset of tyrosine-phosphorylated proteins through its SH2 domain. Acts as an adapter, mediating the association of the p110 catalytic unit of the alpha, beta and delta enzymes to the plasma membrane, where p110 phosphorylates inositol lipids. May play an additional role in the regulation of the actin cytoskeleton. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues.

タンパク質配列:

P27986 P85A_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MSAEGYQYRALYDYKKEREEDIDLHLGDILTVNKGSLVALGFSDGQEARPEEIGWLNGYNETTGERGDFPGTYVEYIGRKKISPPTPKPRPPRPLPVAPGSSKTEADVEQQALTLPDLAEQFAPPDIAPPLLIKLVEAIEKKGLECSTLYRTQSSSNLAELRQLLDCDTPSVDLEMIDVHVLADAFKRYLLDLPNPVIPAAVYSEMISLAPEVQSSEEYIQLLKKLIRSPSIPHQYWLTLQYLLKHFFKLSQTSSKNLLNARVLSEIFSPMLFRFSAASSDNTENLIKVIEILISTEWNERQPAPALPPKPPKPTTVANNGMNNNMSLQDAEWYWGDISREEVNEKLRDTADGTFLVRDASTKMHGDYTLTLRKGGNNKLIKIFHRDGKYGFSDPLTFSSVVELINHYRNESLAQYNPKLDVKLLYPVSKYQQDQVVKEDNIEAVGKKLHEYNTQFQEKSREYDRLYEEYTRTSQEIQMKRTAIEAFNETIKIFEEQCQTQERYSKEYIEKFKREGNEKEIQRIMHNYDKLKSRISEIIDSRRRLEEDLKKQAAEYREIDKRMNSIKPDLIQLRKTRDQYLMWLTQKGVRQKKLNEWLGNENTEDQYSLVEDDEDLPHHDEKTWNVGSSNRNKAENLLRGKRDGTFLVRESSKQGCYACSVVVDGEVKHCVINKTATGYGFAEPYNLYSSLKELVLHYQHTSLVQHNDSLNVTLAYPVYAQQRR

Q92569 P55G_HUMAN:
Protein BLAST With
NCBI/
ExPASy/
Uniprot

MYNTVWSMDRDDADWREVMMPYSTELIFYIEMDPPALPPKPPKPMTSAVPNGMKDSSVSLQDAEWYWGDISREEVNDKLRDMPDGTFLVRDASTKMQGDYTLTLRKGGNNKLIKIYHRDGKYGFSDPLTFNSVVELINHYHHESLAQYNPKLDVKLMYPVSRYQQDQLVKEDNIDAVGKKLQEYHSQYQEKSKEYDRLYEEYTRTSQEIQMKRTAIEAFNETIKIFEEQCHTQEQHSKEYIERFRREGNEKEIERIMMNYDKLKSRLGEIHDSKMRLEQDLKNQALDNREIDKKMNSIKPDLIQLRKIRDQHLVWLNHKGVRQKRLNVWLGIKNEDADENYFINEEDENLPHYDEKTWFVEDINRVQAEDLLYGKPDGAFLIRESSKKGCYACSVVADGEVKHCVIYSTARGYGFAEPYNLYSSLKELVLHYQQTSLVQHNDSLNVRLAYPVHAQMPSLCR

種類予測

種類予測:

Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.

Species

Results

Score

Rabbit

100

Zebrafish

100

Horse

Bovine

Sheep

Dog

Xenopus

Chicken

Pig

Model Confidence:
High(score>80) Medium(80>score>50) Low(score<50) No confidence

Site	PTM Type	Enzyme	Source
	Ubiquitination		Uniprot
S2	Acetylation		Uniprot
Y12	Phosphorylation		Uniprot
S43	Phosphorylation		Uniprot
Y59	Phosphorylation		Uniprot
Y73	Phosphorylation		Uniprot
Y76	Phosphorylation		Uniprot
S83	Phosphorylation	P17612 (PRKACA)	Uniprot
T86	Phosphorylation		Uniprot
S147	Phosphorylation		Uniprot
T148	Phosphorylation		Uniprot
T152	Phosphorylation		Uniprot
S154	Phosphorylation		Uniprot
Y203	Phosphorylation	P07949 (RET)	Uniprot
S208	Phosphorylation		Uniprot
S265	Phosphorylation		Uniprot
S269	Phosphorylation		Uniprot
S279	Phosphorylation		Uniprot
K346	Ubiquitination		Uniprot
Y368	Phosphorylation	P06213 (INSR)	Uniprot
T369	Phosphorylation		Uniprot
K379	Ubiquitination		Uniprot
K419	Ubiquitination		Uniprot
Y426	Phosphorylation		Uniprot
K438	Ubiquitination		Uniprot
K448	Ubiquitination		Uniprot
Y452	Phosphorylation		Uniprot
T454	Phosphorylation		Uniprot
K459	Sumoylation		Uniprot
K459	Ubiquitination		Uniprot
Y463	Phosphorylation		Uniprot
Y467	Phosphorylation		Uniprot
Y470	Phosphorylation		Uniprot
T471	Phosphorylation		Uniprot
T490	Phosphorylation		Uniprot
Y504	Phosphorylation		Uniprot
K506	Ubiquitination		Uniprot
Y508	Phosphorylation	P09619 (PDGFRB)	Uniprot
K513	Ubiquitination		Uniprot
R514	Methylation		Uniprot
K519	Ubiquitination		Uniprot
R523	Methylation		Uniprot
Y528	Phosphorylation		Uniprot
K530	Acetylation		Uniprot
S541	Phosphorylation		Uniprot
Y556	Phosphorylation		Uniprot
K567	Ubiquitination		Uniprot
T576	Phosphorylation		Uniprot
Y580	Phosphorylation	P06213 (INSR)	Uniprot
T603	Phosphorylation		Uniprot
Y607	Phosphorylation	P06213 (INSR) , P12931 (SRC)	Uniprot
S608	Phosphorylation	P42336 (PIK3CA) , P68400 (CSNK2A1)	Uniprot
T623	Phosphorylation		Uniprot
S628	Phosphorylation		Uniprot
S629	Phosphorylation		Uniprot
K633	Ubiquitination		Uniprot
S652	Phosphorylation	Q15139 (PRKD1)	Uniprot
Y657	Phosphorylation		Uniprot
K674	Ubiquitination		Uniprot
Y679	Phosphorylation		Uniprot
Y688	Phosphorylation		Uniprot
S690	Phosphorylation		Uniprot

Site	PTM Type	Enzyme	Source
	Ubiquitination		Uniprot
K78	Ubiquitination		Uniprot
K106	Acetylation		Uniprot
K111	Ubiquitination		Uniprot
K114	Acetylation		Uniprot
K114	Ubiquitination		Uniprot
K155	Ubiquitination		Uniprot
Y163	Phosphorylation		Uniprot
K170	Ubiquitination		Uniprot
K180	Ubiquitination		Uniprot
Y184	Phosphorylation		Uniprot
S186	Phosphorylation		Uniprot
Y188	Phosphorylation		Uniprot
K191	Ubiquitination		Uniprot
Y195	Phosphorylation		Uniprot
Y199	Phosphorylation		Uniprot
Y202	Phosphorylation		Uniprot
T203	Phosphorylation		Uniprot
T222	Phosphorylation		Uniprot
K224	Ubiquitination		Uniprot
K238	Ubiquitination		Uniprot
Y260	Phosphorylation		Uniprot
S273	Phosphorylation		Uniprot
K274	Ubiquitination		Uniprot
K294	Ubiquitination		Uniprot
K299	Ubiquitination		Uniprot
K319	Ubiquitination		Uniprot
Y341	Phosphorylation	P06213 (INSR)	Uniprot
Y373	Phosphorylation		Uniprot
K375	Ubiquitination		Uniprot
K388	Ubiquitination		Uniprot
Y407	Phosphorylation		Uniprot

研究背景

P27986_P85A_HUMAN
Q92569_P55G_HUMAN

機能:

Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling. Modulates the cellular response to ER stress by promoting nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement.

PTMs:

Polyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation.

Phosphorylated. Tyrosine phosphorylated in response to signaling by FGFR1, FGFR2, FGFR3 and FGFR4. Phosphorylated by CSF1R. Phosphorylated by ERBB4. Phosphorylated on tyrosine residues by TEK/TIE2. Dephosphorylated by PTPRJ. Phosphorylated by PIK3CA at Ser-608; phosphorylation is stimulated by insulin and PDGF. The relevance of phosphorylation by PIK3CA is however unclear (By similarity). Phosphorylated in response to KIT and KITLG/SCF. Phosphorylated by FGR.

組織特異性:

Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level).

サブユニット構造:

Heterodimer of a regulatory subunit PIK3R1 and a p110 catalytic subunit (PIK3CA, PIK3CB or PIK3CD). Interacts (via SH2 domains) with CCDC88A/GIV (tyrosine-phosphorylated form); the interaction enables recruitment of PIK3R1 to the EGFR receptor, enhancing PI3K activity and cell migration. Interacts (via SH2 domain) with CSF1R (tyrosine phosphorylated). Interacts with PIK3R2; the interaction is dissociated in an insulin-dependent manner (By similarity). Interacts with XBP1 isoform 2; the interaction is direct and induces translocation of XBP1 isoform 2 into the nucleus in a ER stress- and/or insulin-dependent but PI3K-independent manner. Interacts with FER. Interacts (via SH2 domain) with TEK/TIE2 (tyrosine phosphorylated). Interacts with PTK2/FAK1 (By similarity). Interacts with phosphorylated TOM1L1. Interacts with phosphorylated LIME1 upon TCR and/or BCR activation. Interacts with SOCS7. Interacts with RUFY3. Interacts (via SH2 domain) with CSF1R (tyrosine phosphorylated). Interacts with LYN (via SH3 domain); this enhances enzyme activity (By similarity). Interacts with phosphorylated LAT, LAX1 and TRAT1 upon TCR activation. Interacts with CBLB. The SH2 domains interact with the YTHM motif of phosphorylated INSR in vitro. Also interacts with tyrosine-phosphorylated IGF1R in vitro. Interacts with CD28 and CD3Z upon T-cell activation. Interacts with IRS1 and phosphorylated IRS4, as well as with NISCH and HCST. Interacts with FASLG, KIT and BCR. Interacts with AXL, FGFR1, FGFR2, FGFR3 and FGFR4 (phosphorylated). Interacts with FGR and HCK. Interacts with PDGFRA (tyrosine phosphorylated) and PDGFRB (tyrosine phosphorylated). Interacts with ERBB4 (phosphorylated). Interacts with NTRK1 (phosphorylated upon ligand-binding). Interacts with FAM83B; activates the PI3K/AKT signaling cascade. Interacts with APPL1 and APPL2 (By similarity). Interacts with SRC.

(Microbial infection) Interacts with HIV-1 Nef to activate the Nef associated p21-activated kinase (PAK). This interaction depends on the C-terminus of both proteins and leads to increased production of HIV.

(Microbial infection) Interacts with HCV NS5A.

(Microbial infection) Interacts with herpes simplex virus 1 UL46; this interaction activates the PI3K/AKT pathway.

(Microbial infection) Interacts with herpes simplex virus 1 UL46 and varicella virus ORF12; this interaction activates the PI3K/AKT pathway.

タンパク質ファミリー:

The SH3 domain mediates the binding to CBLB, and to HIV-1 Nef.

Belongs to the PI3K p85 subunit family.

機能:

Binds to activated (phosphorylated) protein-tyrosine kinases through its SH2 domain and regulates their kinase activity. During insulin stimulation, it also binds to IRS-1.

組織特異性:

Highest levels in brain and testis. Lower levels in adipose tissue, kidney, heart, lung and skeletal muscle.

サブユニット構造:

Heterodimer of a regulatory subunit PIK3R3 and a p110 catalytic subunit (PIK3CA, PIK3CB or PIK3CD). Interacts with AXL.

タンパク質ファミリー:

Belongs to the PI3K p85 subunit family.

研究領域

· Cellular Processes > Transport and catabolism > Autophagy - animal. (View pathway)

· Cellular Processes > Cell growth and death > Apoptosis. (View pathway)

· Cellular Processes > Cell growth and death > Cellular senescence. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Focal adhesion. (View pathway)

· Cellular Processes > Cellular community - eukaryotes > Signaling pathways regulating pluripotency of stem cells. (View pathway)

· Cellular Processes > Cell motility > Regulation of actin cytoskeleton. (View pathway)

· Environmental Information Processing > Signal transduction > ErbB signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Ras signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Rap1 signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > cAMP signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > HIF-1 signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > FoxO signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Phosphatidylinositol signaling system.

· Environmental Information Processing > Signal transduction > Sphingolipid signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Phospholipase D signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > mTOR signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > PI3K-Akt signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > AMPK signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > Jak-STAT signaling pathway. (View pathway)

· Environmental Information Processing > Signal transduction > TNF signaling pathway. (View pathway)

· Human Diseases > Drug resistance: Antineoplastic > EGFR tyrosine kinase inhibitor resistance.

· Human Diseases > Drug resistance: Antineoplastic > Endocrine resistance.

· Human Diseases > Drug resistance: Antineoplastic > Platinum drug resistance.

· Human Diseases > Endocrine and metabolic diseases > Type II diabetes mellitus.

· Human Diseases > Endocrine and metabolic diseases > Insulin resistance.

· Human Diseases > Endocrine and metabolic diseases > Non-alcoholic fatty liver disease (NAFLD).

· Human Diseases > Infectious diseases: Bacterial > Bacterial invasion of epithelial cells.

· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).

· Human Diseases > Infectious diseases: Parasitic > Amoebiasis.

· Human Diseases > Infectious diseases: Viral > Hepatitis C.

· Human Diseases > Infectious diseases: Viral > Hepatitis B.

· Human Diseases > Infectious diseases: Viral > Measles.

· Human Diseases > Infectious diseases: Viral > Influenza A.

· Human Diseases > Infectious diseases: Viral > Human papillomavirus infection.

· Human Diseases > Infectious diseases: Viral > HTLV-I infection.

· Human Diseases > Infectious diseases: Viral > Epstein-Barr virus infection.

· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)

· Human Diseases > Cancers: Overview > Viral carcinogenesis.

· Human Diseases > Cancers: Overview > Proteoglycans in cancer.

· Human Diseases > Cancers: Specific types > Colorectal cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Renal cell carcinoma. (View pathway)

· Human Diseases > Cancers: Specific types > Pancreatic cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Endometrial cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Glioma. (View pathway)

· Human Diseases > Cancers: Specific types > Prostate cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Melanoma. (View pathway)

· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia. (View pathway)

· Human Diseases > Cancers: Specific types > Acute myeloid leukemia. (View pathway)

· Human Diseases > Cancers: Specific types > Small cell lung cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Non-small cell lung cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Breast cancer. (View pathway)

· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma. (View pathway)

· Human Diseases > Cancers: Specific types > Gastric cancer. (View pathway)

· Human Diseases > Cancers: Overview > Central carbon metabolism in cancer. (View pathway)

· Human Diseases > Cancers: Overview > Choline metabolism in cancer. (View pathway)

· Organismal Systems > Immune system > Chemokine signaling pathway. (View pathway)

· Organismal Systems > Aging > Longevity regulating pathway. (View pathway)

· Organismal Systems > Aging > Longevity regulating pathway - multiple species. (View pathway)

· Organismal Systems > Development > Axon guidance. (View pathway)

· Organismal Systems > Development > Osteoclast differentiation. (View pathway)

· Organismal Systems > Immune system > Platelet activation. (View pathway)

· Organismal Systems > Immune system > Toll-like receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > Natural killer cell mediated cytotoxicity. (View pathway)

· Organismal Systems > Immune system > T cell receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > B cell receptor signaling pathway. (View pathway)

· Organismal Systems > Immune system > Fc epsilon RI signaling pathway. (View pathway)

· Organismal Systems > Immune system > Fc gamma R-mediated phagocytosis. (View pathway)

· Organismal Systems > Immune system > Leukocyte transendothelial migration. (View pathway)

· Organismal Systems > Nervous system > Neurotrophin signaling pathway. (View pathway)

· Organismal Systems > Nervous system > Cholinergic synapse.

· Organismal Systems > Sensory system > Inflammatory mediator regulation of TRP channels. (View pathway)

· Organismal Systems > Endocrine system > Insulin signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Progesterone-mediated oocyte maturation.

· Organismal Systems > Endocrine system > Estrogen signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Prolactin signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Thyroid hormone signaling pathway. (View pathway)

· Organismal Systems > Endocrine system > Regulation of lipolysis in adipocytes.

· Organismal Systems > Endocrine system > Relaxin signaling pathway.

· Organismal Systems > Excretory system > Aldosterone-regulated sodium reabsorption.

· Organismal Systems > Digestive system > Carbohydrate digestion and absorption.

参考文献

1). Engineering micro oxygen factories to slow tumour progression via hyperoxic microenvironments. Nature Communications, 2022 (PubMed: 35918337) [IF=16.6]

2). MiR-146b-5p enriched bioinspired exosomes derived from fucoidan-directed induction mesenchymal stem cells protect chondrocytes in osteoarthritis by targeting TRAF6. Journal of nanobiotechnology, 2023 (PubMed: 38105181) [IF=10.2]

Application: WB Species: Rat Sample: chondrocytes

Fig. 7 Enriched miR-146b-5p in F-MSCs-Exo inhibits PI3K/AKT/mTOR pathway by targeting TRAF6. (A, B) Western blot analysis was performed to detect the impact of F-MSCs-Exo on TRAF6 and the PI3K/AKT/mTOR pathway in rat chondrocytes. (C, D) The expression of TRAF6 was quantitatively analyzed using immunofluorescence staining and ImageJ software (scale bar = 10 μm). (E, F) Direct visualization of chondrocytes treated with nc-inhibitor and miR-146b-5p-inhibitor was performed using Alcian blue staining and safranin staining. (G, H) Western blot analysis was conducted to examine the expressions of TRAF6 and the PI3K/AKT/mTOR pathway in chondrocytes after treatment with nc-inhibitor and miR-146b-5p-inhibitor. (ns, no significant difference; *p

3). Morinda officinalis oligosaccharides mitigate depression-like behaviors in hypertension rats by regulating Mfn2-mediated mitophagy. Journal of Neuroinflammation, 2023 (PubMed: 36765376) [IF=9.3]

Application: WB Species: Rat Sample:

Fig. 6 Mfn2 mediated inactivation of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) involved in the pro-autophagic effect of Morinda officinalis oligosaccharides. A Mfn2 expression was determined by quantitative polymerase chain reaction (qPCR) and western blotting. B The PI3K/Akt/mTOR pathway-related protein levels were determined by western blotting. C Fluorescent localization of the autophagosome (yellow) and autolysosome (red) using the GFP-mRFP-LC3 probe. D Autophagy-related protein levels, including LC3 and p62, were determined by western blotting. Data are shown as the mean ± standard deviation of three independent experiments. *p

4). ACT001, a novel PAI-1 inhibitor, exerts synergistic effects in combination with cisplatin by inhibiting PI3K/AKT pathway in glioma. Cell Death & Disease, 2019 (PubMed: 31591377) [IF=9.0]

Application: WB Species: Sample: glioma cells

Fig. 5| ACT001 inhibits glioma cells through the PI3K/AKT signalling pathway.f The PI3K/AKT pathway was detected in glioma cells before (Con) and 24 h after PAI-039 treatment at the indicated concentrations.The results were obtained from three independent experiments, and each experiment was performed in triplicate. Data are represented as the mean ± standard error of the mean (*P < 0.05, **P < 0.01)

Application: IHC Species: mouse Sample: Tumour

Fig. 7| ACT001 enhances the antitumour effect of cisplatin in vivo. a Xenograft assays in the mice treated with control, ACT001, cisplatin and ACT001 + cisplatin. b Tumour volume changes in the mice treated with control, ACT001, cisplatin and ACT001 + cisplatin. c Body weight changes in the mice treated with control, ACT001, cisplatin and ACT001 + cisplatin. d IHC analysis of the PI3K, p-PI3K, AKT and p-AKT levels. Compared with the control group, the staining of p-PI3K and p-AKT was lighter in the ACT001 treatment groups. In the ACT001 + cisplatin treatment group, the staining of p-PI3K and p-AKT was lighter than in the ACT001-treated group.

5). miRNA-92a-3p Regulates Osteoblast Differentiation in Patients with Concomitant Limb Fractures and Traumatic Brain Injury Through IBSP/PI3K-AKT Inhabitation. Molecular Therapy-Nucleic Acids, 2021 (PubMed: 33717654) [IF=8.8]

Application: WB Species: mouse Sample: MC3T3-E1 cells

Figure 5. |PI3K/AKT signaling is involved in IBSP-regulated osteoblast differentiation(A)Transfection of agomiRNA-92a-3p, antagomiRNA-92a-3p, agomiRNA-NC, antagomiRNA-NC, and Lipofectamine 3000 control (200 mm) in MC3T3-E1 cells for 48 h.Western blot detection of the expression of PI3K and AKT after transfection.

Application: WB Species: Mice Sample: MC3T3-E1 cells

Figure 5 PI3K/AKT signaling is involved in IBSP-regulated osteoblast differentiation (A) Transfection of agomiRNA-92a-3p, antagomiRNA-92a-3p, agomiRNA-NC, antagomiRNA-NC, and Lipofectamine 3000 control (200 μm) in MC3T3-E1 cells for 48 h. Western blot detection of the expression of PI3K and AKT after transfection. (B) Western blot detection of IBSP, p-PI3K, and p-AKT levels after transfection with siRNA-NC, siRNA-IBSP, and controls for 48 h. (C–G) Transfection with Lipofectamine 3000, siRNA-NC, siRNA-PI3K, or siRNA-AKT for 48 h. (C) Protein-expression levels of p-AKT, AKT, p-PI3K, and p-PI3K using western blotting. (D–G) qPCR analysis of Col1a1 (D), ALP (E), OCN (F), and Runx2 (G) expression in bone precursor cells. (H) Western blot analysis of Col1a1, ALP, OCN, and Runx2 levels 48 h after transfection. (I) Alizarin red staining of MC3T3-E1 cells 3 weeks after transfection. (J) ALP staining of MC3T3-E1 cells 2 weeks after transfection. n = 3; data are presented as mean ± SD (∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001; # no significance).

6). Eicosapentaenoic acid-mediated activation of PGAM2 regulates skeletal muscle growth and development via the PI3K/AKT pathway. International journal of biological macromolecules, 2024 (PubMed: 38641281) [IF=8.2]

Application: WB Species: Mouse Sample:

Fig. 9. EPA targets PGAM2 and activates the PI3K/AKT pathway. A. Heatmap of differentially expressed genes as determined via RNA-seq. B. KEGG pathway analysis of differentially expressed genes. C. The MuSC protein levels of the components of the PI3K/AKT pathway after EPA treatment and PGAM2 interference were measured by western blotting (n = 3). D. ELISA for the effect of EPA after PGAM2 knockdown (n = 3). E. Effect of EPA on the protein levels of components in the PI3K/AKT pathway after knockdown as analyzed by western blotting (n = 2). F–G. Effects of EPA and a PI3K/AKT pathway inhibitor (GDC-0941) on the protein levels of components of the PI3K/AKT pathway in MuSCs (F) and C2C12 cells (G) as determined by western blotting (n = 3). H. Immunofluorescence staining of MyHC to evaluate the differentiation of MuSCs and C2C12 cells. Results are mean ± SEM. ANOVA post-hoc analysis was performed using Fisher's least significant difference test.

7). Cathepsin S activity controls chronic stress-induced muscle atrophy and dysfunction in mice. Cellular and Molecular Life Sciences, 2023 (PubMed: 37589754) [IF=8.0]

Application: WB Species: Mouse Sample:

Fig. 4 CTSS deficiency ameliorated stress-related anabolic and catabolic molecular alterations. a–e: Representative immunoblotting images and quantitative data for CTSS, IGF-1, IRS-2, p-PI3K, p-Akt, p-mTOR, p-FoxO1α, MuRF-1, MAFbx1, PGC-1α, PPAR-γ, C-caspase-3, and Bcl-2 in GAS muscles at Day 14 after stress (n = 3). Data are mean ± SEM, and p-values were determined by a one-way ANOVA followed by Bonferroni post hoc tests (b–e). CW: CTSS+/+ control mice, CK: CTSS−/− control mice, SW: 14-day-stressed CTSS+/+ mice, SK: 14-day-stressed CTSS−/− mice. *p

8). Agrimoniin sensitizes pancreatic cancer to apoptosis through ROS-mediated energy metabolism dysfunction. Phytomedicine, 2022 (PubMed: 34785107) [IF=7.9]

9). Xanthotoxol suppresses non-small cell lung cancer progression and might improve patients' prognosis. PHYTOMEDICINE, 2022 (PubMed: 35932608) [IF=7.9]

10). Liensinine alleviates LPS-induced acute lung injury by blocking autophagic flux via PI3K/AKT/mTOR signaling pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2023 (PubMed: 37922654) [IF=7.5]

Application: WB Species: Human Sample: Beas-2B cells

Fig. 4. Liensinine blocks autophagic flux through the PI3K/AKT/mTOR pathway in Beas-2B cells with LPS treatment. Western blot detected the levels of p-PI3K, PI3K, p-AKT, AKT, p-mTOR, mTOR (A-C). The values presented are mean ± SEM, *P

Restrictive clause

Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.

For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.

Phospho-PI3K p85 (Tyr458)[Tyr467]/p55 (Tyr199) Antibody - #AF3242

関連製品情報

関連ダウンロード

MSDS

説明書

COA